Abstracts from Invited Speakers / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S1-S8 S7 hypertension, and insulin resistance, suggesting that systemic factors could also play a role in the genesis of OA joint damage. A number of defined metabolic diseases may also lead to non-inflammatory arthropathy with radiographic features predominantly of OA. The principal conditions that predispose to secondary OA are ochronosis, wilson's disease, acromegaly and hereditary hemochromatosis (HH). The most common form of HH is an autosomal recessive iron overload disorder associated with mutation of the HFE gene. Affected individuals may present with a severe arthropathy mimicking OA, typically involving the second and third metacarpophalangeal joints, which may seriously affect quality of life. Other metabolic diseases, like chronic hypomagnesaemia or primary hyperparathyroidism may lead to deposition of calcium pyrophosphate crystals within cartilage. These deposits, named chondrocalcinosis when identified by X-Rays, are associated with OA, which may present with more inflammatory symptoms, an atypical distribution and prominent cyst and osteophyte formation on radiographs.
Despite all the advances in bone and cartilage biology, particularly in the recent bone and joint decade, there are still some deficiencies in our understanding of the pathogenesis of osteoarthritis (OA), as well as our ability to diagnose and treat OA. Nanomedicine is expected to improve the ADL of patients with OA through the advances in the technology for diagnosis and treatment.
(1) Oxidative DNA damage contributes to aging and degeneration of articular cartilage. During the development of OA, mechanical and chemical stresses on articular cartilage change the stable cellular activities of chondrocytes and produce excess amounts of reactive oxygen species (ROS) as well as proinflammatory cytokines and chemokines. Studies have provided ample confirmation of the accumulation of ROS and the chondrocyte aging in degenerated articular cartilage. Our recent study revealed the potential involvement of accumulation of 8-Oxoguanine, an oxidized form of guanine, and impairment of mitochondrial DNA repair enzymes in the pathogenesis of OA. 8-Oxoguanine is produced by ROS in large amounts in both DNA and nucleotide pools and is a major causative lesion for mutagenesis by ROS in a variety of diseases. We observed the increased level of 8-Oxoguanine and decreased level of Ogg1 in osteoarthritic chondrocytes of degenerated cartilage in comparison with chondrocytes of intact cartilage in animal models of OA and in patients with OA, suggesting the involvement of the accumulation of 8-Oxoguanine in articular chondrocytes and down-regulation of its repair enzyme Ogg1 in the degeneration of articular cartilage in OA. We found that overexpression of mitochondria-targeted human hOgg1 in human osteoarthritis chondrocytes prevents oxidant-induced mitochondrial dysfunction, OA relating catabolic stress-induced caspase-9 activation and apoptosis in vitro. Furthermore, hOgg1 silencing using siRNA reduced chondrocyte activity and augments apoptosis in human ostearthritic chondrocytes.
(2) Application of nanotechnology to chondroprotection. In the previous studies, we have focused on nanocarbon particle, fullerene (C60), which acts a strong free radical scavenger, as an anti-oxidative agent, to prevent the degeneration of articular cartilage in OA. We have demonstrated that water-soluble fullerene has a potential as a protective agent against the catabolic stress-induced degeneration of articular cartilage both in vitro andin vivo OA models. In this paper, we demonstrate that mitochondrial 8-Oxoguanine DNA glycosylase regulates the cellular function and survival of osteoarthritic chondrocytes in response to catabolic stresses in OA. In addition, we show that C60 fullerene may influence the expressions of mitochondrial DNA repair enzymes and their functions in osteoarthritic chondrocytes, suggesting that C60 fullerene has a therapeutic potential, as a nanomedicine, to protect against the degeneration of articular cartilage in OA. We would like to conclude the pathomechanism of OA in terms of the chondrocyte ability and function in response to oxidative stress by augmenting DNA repair.
(3) Application of bone and cartilage imaging. Magnetic resonance imaging (MRI) is now thought an effective tool in the image diagnosis of OA.
However, spatial resolution of MRI is limited to a span of one to several millimeters. While conventional X-ray imaging system has been used in the image diagnosis of various diseases, cartilage cannot be depicted with them. There has been a strong call for an X-ray imaging technology that can depict cartilage. More recently, Kido K. et al. demonstrated a novel X-ray imaging system which it would be easier to detect the onset of a disease, to diagnose the stage of the disease, and to monitor the effect of treatment for bone and cartilage diseases. We also show their excellent technology of image diagnosis, an X-ray Talbot-Lau interferometry, for degenerated bone and cartilage.
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REGENERATIVE MEDICINE: THE BIOLOGICAL REPAIR OF JOINT SURFACES F. Luyten
Univ. Hosp. KULeuven, Leuven, Belgium
Regenerative Medicine aims to reconstruct or regenerate damaged or lost tissue function due to trauma, disease or congenital defects, ideally without tissue scarring. As articular cartilage does not heal, restoring damaged joint surfaces has been a typical example where regmed approaches have been explored extensively for over 15 years. With the adoption of a new regulatory framework for Advanced Therapy Medicinal Products (ATMP) at the end of 2007, also for cellular and/or combinations products, the path of product development has become more clear. Characterization of the cellular product by viability, identity, potency and purity together with appropriate preclinical and toxicity studies, and validation of a good manufacturing process (GMP) are all part of and critical in this track of development. So far, one autologous cartilage cell product has obtained central regulatory approval for the repair of symptomatic articular cartilage defects in the knee. The data of the short and long term follow up confirm structural superiority over microfracture, considered the standard of care. Clinical superiority over microfracture is particularly striking for patients with a relatively recent medical history (less then 5 years). Additional explorative trials for cartilage repair using variations on autologous cell based approaches, including the use of collagen membranes, have provided valuable information about study design, mechanisms of repair and clinical outcome and have revealed that further improvements could be achieved. Besides expanded autologous articular chondrocytes, the use of allogenic progenitor cell populations are now considered as an important goal. Some promising results have been reported in animal studies using progenitor and mesenchymal cell populations (MSC) in post-traumatic models of osteoarthritis (OA). However, before being able to evaluate the role of cellular therapies in OA, more detailed information is needed on many aspects including mechanisms of action, the fate of the cells, choice of cell type and tissue origin, and culture parameters. Indeed, the mechanisms by which MSC may contribute to tissue repair in OA are diverse and include trophic effects, anti-inflammatory effects and direct tissue repair through engraftment. The use of biomarkers to identify mechanistic events and patients responding to treatment is an important step forward for these more sophisticated regenerative approaches in OA. In conclusion, there is hope for regenerative medicine, in particular in joint an skeletal applications.
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IMPACT OF OSTEOARTHRITIS PAIN ON THE BRAIN
T.J. Schnitzer, A.V. Apkarian Northwestern Univ. Feinberg Sch. of Med., Chicago, IL Purpose: Chronic pain is a hallmark of osteoarthritis (OA), yet little is known about its properties and representation in the brain. Previous studies from our group in other pain states have demonstrated distinct global and local brain morphological changes. The current investigations in patients with OA were undertaken to compare this condition and ascertain its specificity in comparison to other clinical chronic pain conditions. Methods: Psychophysical measurements to examine the magnitude and temporal properties of pain perception were coupled with fMRI to evaluate brain activity in healthy controls and OA patients and relate brain activity to clinical parameters of the disease. Voxel-based morphometry was utilized to determine gray matter changes in OA and compared to other chronic
